Profile data is unavailable for this security.
About the company
Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
- Revenue in USD (TTM)--
- Net income in USD--
- Incorporated2019
- Employees0.00
- LocationEvotec SEEssener Bogen 7HAMBURG 22419GermanyDEU
- Phone+49 40560810
- Fax+49 4 056081222
- Websitehttps://www.evotec.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dynavax Technologies Corp | 260.81m | 20.48m | 1.62bn | 408.00 | 101.25 | 2.38 | 64.90 | 6.23 | 0.1221 | 0.1221 | 1.83 | 5.19 | 0.2563 | 0.80 | 4.36 | 639,242.60 | 2.01 | 4.16 | 2.14 | 5.71 | 82.85 | 64.83 | 7.85 | 9.19 | 12.34 | -- | 0.247 | 0.00 | -67.86 | 95.19 | -102.18 | -- | -23.03 | -- |
| Recursion Pharmaceuticals Inc | 65.18m | -377.75m | 1.65bn | 500.00 | -- | 3.13 | -- | 25.29 | -1.53 | -1.53 | 0.2631 | 1.83 | 0.096 | -- | 24.06 | 130,368.00 | -55.66 | -- | -65.45 | -- | 35.07 | -- | -579.51 | -- | -- | -- | 0.0519 | -- | 11.88 | -- | -36.99 | -- | -- | -- |
| Xencor Inc | 85.16m | -198.24m | 1.69bn | 280.00 | -- | 2.33 | -- | 19.80 | -3.20 | -3.20 | 1.37 | 10.35 | 0.0967 | -- | 2.61 | 304,157.20 | -22.89 | -3.70 | -24.90 | -4.12 | -- | -- | -236.81 | -15.92 | -- | -- | 0.0243 | -- | 2.28 | 32.90 | -128.50 | -- | 18.36 | -- |
| Structure Therapeutics Inc (ADR) | 0.00 | -110.55m | 1.72bn | 148.00 | -- | 1.92 | -- | -- | -2.21 | -2.21 | 0.00 | 15.66 | 0.00 | -- | -- | 0.00 | -19.23 | -- | -20.17 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -69.62 | -- | -- | -- |
| Arvinas Inc | 161.10m | -308.60m | 1.73bn | 445.00 | -- | 2.94 | -- | 10.71 | -4.79 | -4.79 | 2.38 | 8.53 | 0.1448 | -- | 14.01 | 362,022.50 | -27.73 | -22.01 | -37.81 | -26.47 | -- | -- | -191.56 | -316.55 | -- | -- | 0.001 | -- | -40.26 | 40.53 | -30.02 | -- | 0.4852 | -- |
| Celldex Therapeutics, Inc. | 9.98m | -154.08m | 1.74bn | 160.00 | -- | 2.21 | -- | 174.37 | -2.57 | -2.57 | 0.164 | 11.85 | 0.0181 | -- | 18.07 | 62,350.00 | -27.93 | -29.65 | -29.53 | -31.42 | -- | -- | -1,544.48 | -1,747.94 | -- | -- | 0.00 | -- | 192.02 | -6.32 | -25.91 | -- | 17.46 | -- |
| Fortrea Holdings Inc | 2.77bn | -233.60m | 1.75bn | 15.50k | -- | 1.16 | -- | 0.6297 | -2.62 | -3.40 | 31.09 | 16.87 | 0.6954 | -- | 3.20 | 154,155.60 | -5.85 | -- | -7.29 | -- | 18.49 | -- | -8.42 | -- | -- | -0.6141 | 0.4263 | -- | 0.4167 | -- | -101.76 | -- | -- | -- |
| Evotec SE (ADR) | -100.00bn | -100.00bn | 1.89bn | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Disc Medicine Inc | 0.00 | -103.48m | 1.89bn | 74.00 | -- | 4.04 | -- | -- | -3.97 | -3.97 | 0.00 | 15.73 | 0.00 | -- | -- | 0.00 | -23.74 | -- | -24.88 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -63.22 | -- | -- | -- |
| MannKind Corp | 267.20m | 21.57m | 1.90bn | 414.00 | 97.02 | -- | 67.65 | 7.12 | 0.0711 | 0.0711 | 0.9277 | -0.7612 | 0.6812 | 2.79 | 13.36 | 645,410.60 | 5.50 | -26.07 | 7.00 | -37.80 | 71.91 | 59.68 | 8.07 | -57.61 | 4.17 | 1.89 | 1.77 | -- | 99.42 | 48.17 | 86.34 | -- | 160.47 | -- |
| Beam Therapeutics Inc | 349.64m | -143.59m | 1.95bn | 436.00 | -- | 2.46 | -- | 5.58 | -1.72 | -1.72 | 4.27 | 9.58 | 0.284 | -- | -- | 801,933.50 | -11.67 | -24.54 | -13.84 | -29.26 | -- | -- | -41.07 | -211.96 | -- | -- | 0.00 | -- | 520.01 | -- | 54.16 | -- | 20.78 | -- |
| Mirum Pharmaceuticals Inc | 307.03m | -99.81m | 2.07bn | 311.00 | -- | 8.99 | -- | 6.76 | -2.12 | -2.12 | 6.51 | 4.84 | 0.4657 | 3.83 | 5.28 | 1,162,985.00 | -15.14 | -38.93 | -17.70 | -44.88 | 72.68 | -- | -32.51 | -190.71 | 3.15 | -- | 0.5701 | -- | 141.85 | -- | -20.45 | -- | 21.81 | -- |
| Wave Life Sciences Ltd | 53.61m | -142.52m | 2.09bn | 266.00 | -- | 15.03 | -- | 38.97 | -1.11 | -1.11 | 0.427 | 1.01 | 0.192 | -- | 15.32 | 201,541.40 | -51.04 | -56.98 | -99.07 | -102.38 | -- | -- | -265.84 | -353.20 | -- | -- | 0.00 | -- | 3,005.10 | 51.04 | 64.46 | -- | -35.44 | -- |
| CG Oncology Inc | 684.00k | -78.29m | 2.17bn | 61.00 | -- | 4.07 | -- | 3,171.45 | -1.19 | -1.19 | 0.0104 | 7.95 | 0.0018 | -- | 9.91 | 11,213.12 | -18.93 | -- | -19.63 | -- | -- | -- | -10,578.22 | -- | -- | -- | 0.00 | -- | 6.81 | -- | -54.83 | -- | -- | -- |
Data as of Nov 21 2024. Currency figures normalised to Evotec SE's reporting currency: US Dollar USD
3.74%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Wellington Management Co. LLPas of 30 Sep 2024 | 2.37m | 2.67% |
| Wellington Management Canada ULCas of 30 Sep 2024 | 262.78k | 0.30% |
| DCF Capital LLCas of 30 Sep 2024 | 217.06k | 0.24% |
| Mediolanum International Funds Ltd.as of 30 Sep 2024 | 140.38k | 0.16% |
| Morgan Stanley & Co. LLCas of 30 Sep 2024 | 77.07k | 0.09% |
| Millennium Management LLCas of 30 Sep 2024 | 71.02k | 0.08% |
| Goldman Sachs & Co. LLC (Private Banking)as of 30 Sep 2024 | 57.14k | 0.06% |
| Aperio Group LLCas of 30 Sep 2024 | 51.16k | 0.06% |
| Morgan Stanley Smith Barney LLC (Investment Management)as of 30 Sep 2024 | 45.39k | 0.05% |
| Clear Harbor Asset Management LLCas of 30 Sep 2024 | 28.60k | 0.03% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
